UK Foundation Outlines Recommendations for Effective ctDNA Testing in Lung Cancer

NEW YORK (GenomeWeb) – UK health policy think tank PHG Foundation has released a report detailing recommendations on developing effective testing services for circulating tumor DNA in lung cancer patients.

The report was informed by a workshop the foundation held in March 2017 — which included input from clinicians, UK National Health Service clinical scientists, and representatives from the life science and biotech industry — to identify and focus on the most pressing issues affecting the implementation of effective and equitable ctDNA testing.

Specifically, the group focused on how the testing could help a subset of patients with non-small cell lung cancer (NSCLC) who can be treated with tyrosine kinase inhibitors that target mutations in the EGFR gene. “These patients require a genetic test in order for the clinician to prescribe the therapy. Due to the challenges associated with carrying out a biopsy to collect a solid tumor sample for testing, many patients miss out on genetic testing,” the report noted. “In patients for whom biopsies are possible approximately 30 percent of biopsies fail or do not yield enough material for a genetic test.”

The report concludes that ctDNA testing can help these patients and perhaps bring them closer to

Be the first to comment

Leave a Reply

Your email address will not be published.